Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD4 | P01730 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906206 | 0.95 | CD4 (0.45) | CD4MAPTALDH1A1LMNAHSD11B1 | |
| SCHEMBL9540293 | 0.87 | ALDH1A1 (0.49) | MAPTALDH1A1LMNAKMT2A | |
| SCHEMBL4592308 | 0.85 | MAPT (0.43) | CD4MAPTALDH1A1LMNAHSD11B1 | |
| SCHEMBL4092772 | 0.81 | LMNA (0.52) | MAPTALDH1A1LMNAKMT2A | |
| SCHEMBL9906200 | 0.80 | LMNA (0.52) | MAPTALDH1A1LMNAKMT2A | |
| SCHEMBL19157440 | 0.79 | MAPT (0.41) | CD4MAPTALDH1A1LMNAHSD11B1 | |
| SCHEMBL4097232 | 0.78 | LMNA (0.51) | MAPTALDH1A1LMNAKMT2A | |
| SCHEMBL9024755 | 0.76 | CD4 (0.52) | CD4ALDH1A1LMNAKMT2A | |
| SCHEMBL9216667 | 0.76 | CD4 (0.71) | CD4ALDH1A1LMNAKMT2A | |
| SCHEMBL8192516 | 0.75 | GAA (0.55) | MAPTALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004642-B1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | Nordion (Canada) Inc (CA) | 2017-07-26 | — | — | EP | disclosed |
| US-8518715-B2 | Bifunctional polyazamacrocyclic chelating agents | NORDION (CANADA) INC. (CA) | 2013-08-27 | — | — | US | disclosed |
| US-8518715-B2 | Bifunctional polyazamacrocyclic chelating agents | NORDION (CANADA) INC. (CA) | 2013-08-27 | — | — | US | disclosed |
| US-20120276001-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | Nordion (Canada) Inc (CA) | 2012-11-01 | — | — | US | disclosed |
| US-20120276001-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | Nordion (Canada) Inc (CA) | 2012-11-01 | — | — | US | disclosed |
| US-8198101-B2 | Bifunctional polyazamacrocyclic chelating agents | NORDION (CANADA) INC. (CA) | 2012-06-12 | — | — | US | disclosed |
| US-8198101-B2 | Bifunctional polyazamacrocyclic chelating agents | NORDION (CANADA) INC. (CA) | 2012-06-12 | — | — | US | disclosed |
| US-20090202521-A1 | Bifunctional Polyazamacrocyclic Chelating Agents | MDS (CANADA) INC. (CA) | 2009-08-13 | — | — | US | disclosed |
| WO-2007104135-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | MDS (CANADA) INC. (CA) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202521-A1 | Bifunctional Polyazamacrocyclic Chelating Agents | LPXN, FCGRT, POLQ | CD4 612/4885MAPT 3956/4885ALDH1A1 2764/4885 |
| US-20120276001-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | LPXN, FCGRT, F13A1 | CD4 779/4885MAPT 3836/4885ALDH1A1 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.